BridGene Biosciences is a biotechnology company that leverages its proprietary IMTAC™ (Isobaric Mass-Tagged Affinity Characterization) chemoproteomic platform to discover covalent small-molecule therapeutics against historically undruggable targets. Its lead candidate, BGC-515, is a covalent TEAD inhibitor now in clinical development for solid tumors and slated to progress into Phase 2 with the new funding. The company is also advancing a second, unnamed program expected to enter the clinic in 2027 and is building a broader pipeline across oncology and autoimmune diseases. BridGene plans to use its expanded resources to deepen strategic collaborations that further validate the versatility of its platform in oncology, immunology and neurology. While no revenue or patient metrics were disclosed, the firm emphasizes translating its chemical biology discoveries into transformative therapies. The latest financing underscores investor confidence in BridGene’s platform approach and clinical pipeline.

Total raised

$79M

Funding rounds

3

Latest round

Series B

Latest activity

Oct 2025